Vaccine administration is under way worldwide to combat the current COVID-19 pandemic. The newly developed vaccines are highly effective with minimal adverse effects. Recently, the AstraZeneca ChadOx1 nCov-19 vaccine has raised public alarm with concerns regarding the rare, but serious, development of thrombotic events, now known as vaccine-induced immune thrombotic thrombocytopenia (VITT). These thrombotic events appear similar to heparin-induced thrombocytopenia, both clinically and pathologically. In this manuscript, the ISTH SSC Subcommittee on Platelet Immunology outlines guidelines on how to recognize, diagnose and manage patients with VITT.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of Thrombosis and Haemostasis|
|State||Published - Jun 2021|
- AstraZeneca ChadOx1 nCov-19 vaccine
- platelet activation
ASJC Scopus subject areas